Atsushi Yamauchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Atsushi Yamauchi has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Yasufumi Kataoka
Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan
14 shared publications - Junichi Matsumoto
Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan
12 shared publications - Mitsuhisa Koga
Department of Drug Delivery, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan
9 shared publications - Shinya Dohgu
Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan
9 shared publications - Fuyuko Takata
Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan
8 shared publications Yasufumi Kataoka
Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan
7 shared publications
Latest Publications
- Open Access
- 23 March 2024
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 38, 101688
Nalmefene, an opioid receptor modulator, aggravates atherosclerotic plaque formation in apolipoprotein E knockout mice by enhancing oxidized low-density lipoprotein uptake in macrophages
- 23 March 2024
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 38, 101688
Open AccessNalmefene, an opioid receptor modulator, aggravates atherosclerotic plaque formation in apolipoprotein E knockout mice by enhancing oxidized low-density lipoprotein uptake in macrophages
- Open Access
- 29 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 10842
Bortezomib Increased Vascular Permeability by Decreasing Cell–Cell Junction Molecules in Human Pulmonary Microvascular Endothelial Cells
Bortezomib (BTZ), a chemotherapeutic drug used to treat multiple myeloma, induces life-threatening side effects, including severe pulmonary toxicity. However, the mechanisms underlying these effects remain unclear. The objectives of this study were to (1) investigate whether BTZ influences vascular permeability and (2) clarify the effect of BTZ on the expression of molecules associated with cell–cell junctions using human pulmonary microvascular endothelial cells in vitro. Clinically relevant concentrations of BTZ induced limited cytotoxicity and increased the permeability of human pulmonary microvascular endothelial cell monolayers. BTZ decreased the protein expression of claudin-5, occludin, and VE-cadherin but not that of ZO-1 and β-catenin. Additionally, BTZ decreased the mRNA expression of claudin-5, occludin, ZO-1, VE-cadherin, and β-catenin. Our results suggest that BTZ increases the vascular permeability of the pulmonary microvascular endothelium by downregulating cell–cell junction molecules, particularly claudin-5, occludin, and VE-cadherin.
- 29 June 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 10842
Open AccessBortezomib Increased Vascular Permeability by Decreasing Cell–Cell Junction Molecules in Human Pulmonary Microvascular Endothelial Cells
Bortezomib (BTZ), a chemotherapeutic drug used to treat multiple myeloma, induces life-threatening side effects, including severe pulmonary toxicity. However, the mechanisms underlying these effects remain unclear. The objectives of this study were to (1) investigate whether BTZ influences vascular permeability and (2) clarify the effect of BTZ on the expression of molecules associated with cell–cell junctions using human pulmonary microvascular endothelial cells in vitro. Clinically relevant concentrations of BTZ induced limited cytotoxicity and increased the permeability of human pulmonary microvascular endothelial cell monolayers. BTZ decreased the protein expression of claudin-5, occludin, and VE-cadherin but not that of ZO-1 and β-catenin. Additionally, BTZ decreased the mRNA expression of claudin-5, occludin, ZO-1, VE-cadherin, and β-catenin. Our results suggest that BTZ increases the vascular permeability of the pulmonary microvascular endothelium by downregulating cell–cell junction molecules, particularly claudin-5, occludin, and VE-cadherin.
- Open Access
- 25 May 2023
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 34, 101489
Association of T cell infiltration and morphological change of thymus gland with the aggravation of pulmonary emphysema in testosterone deficiency
- 25 May 2023
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 34, 101489
Open AccessAssociation of T cell infiltration and morphological change of thymus gland with the aggravation of pulmonary emphysema in testosterone deficiency
- Open Access
- 1 January 2022
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 95, 2-07
Nalmefene, a reducing alcohol consumption drug, enhanced oxLDL uptake in macrophages and aggravates atherosclerotic plaque formation in apolipoprotein E knockout mice.
Backgrounds: Nalmefene, an opioid receptor modulator, is one of the reducing alcohol consumption drugs for patients with alcohol dependence. Opioid receptors have been reported to involve in peripheral inflammatory diseases such as colitis and arthritis in animal models. The uptake of oxidized low-density lipoprotein (oxLDL) in macrophages in atherosclerotic plaques develops atherosclerosis, one of the inflammatory diseases. In this study, we determined if nalmefene increases risk of atherosclerosis formation using apolipoprotein E knockout (ApoE KO) mice and peritoneal macrophages.Methods and results: ApoE KO mice (8-week-old) were fed a high-fat diet and intraperitoneally administrated with vehicle (saline) or nalmefene (1 mg and 3 mg kg-1 day-1) for 21 days. Atherosclerotic lesions were histologically analyzed by oil red O-staining and immunohistochemistry using anti-MOMA2 (monocytes / macrophages) antibody. The atherosclerotic plaque formation in ApoE KO mice was dose-dependently progressed by nalmefene treatment. In addition, nalmefene significantly increased the MOMA2-positive area in aorta in ApoE KO mice. Next, to examine the effects of nalmefene on oxLDL uptake in peritoneal macrophage, peritoneal macrophages were treated with nalmefene (300 μg / mL) for 24 h and then DiI-labeled oxLDL (DiI-oxLDL) was added to the cells for 4 h. Nalmefene significantly increased DiI-oxLDL uptake in cells compared with vehicle (P<0.01).Conclusion: Nalmefene may progress the atherosclerotic plaque formation via enhancing oxLDL uptake in macrophages.
- 1 January 2022
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 95, 2-07
Open AccessNalmefene, a reducing alcohol consumption drug, enhanced oxLDL uptake in macrophages and aggravates atherosclerotic plaque formation in apolipoprotein E knockout mice.
Backgrounds: Nalmefene, an opioid receptor modulator, is one of the reducing alcohol consumption drugs for patients with alcohol dependence. Opioid receptors have been reported to involve in peripheral inflammatory diseases such as colitis and arthritis in animal models. The uptake of oxidized low-density lipoprotein (oxLDL) in macrophages in atherosclerotic plaques develops atherosclerosis, one of the inflammatory diseases. In this study, we determined if nalmefene increases risk of atherosclerosis formation using apolipoprotein E knockout (ApoE KO) mice and peritoneal macrophages.Methods and results: ApoE KO mice (8-week-old) were fed a high-fat diet and intraperitoneally administrated with vehicle (saline) or nalmefene (1 mg and 3 mg kg-1 day-1) for 21 days. Atherosclerotic lesions were histologically analyzed by oil red O-staining and immunohistochemistry using anti-MOMA2 (monocytes / macrophages) antibody. The atherosclerotic plaque formation in ApoE KO mice was dose-dependently progressed by nalmefene treatment. In addition, nalmefene significantly increased the MOMA2-positive area in aorta in ApoE KO mice. Next, to examine the effects of nalmefene on oxLDL uptake in peritoneal macrophage, peritoneal macrophages were treated with nalmefene (300 μg / mL) for 24 h and then DiI-labeled oxLDL (DiI-oxLDL) was added to the cells for 4 h. Nalmefene significantly increased DiI-oxLDL uptake in cells compared with vehicle (P<0.01).Conclusion: Nalmefene may progress the atherosclerotic plaque formation via enhancing oxLDL uptake in macrophages.
- Open Access
- 1 January 2022
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 95, 2-141
Moxifloxacin exacerbates aortic aneurysm and aortic dissection by weakening the aortic media
Backgrounds: Aortic aneurysm and dissection (AAD) are caused by weaking vessel wall and depletion of vascular smooth muscle cells (VSMC). Osteopontin (OPN) causes the onset and exacerbation of AAD by increasing expression of matrix metalloproteinases (MMPs). Fluoroquinolones are the most common used antibiotics. On the other hand, clinical studies have indicated that fluoroquinolones may be associated with an increased risk of AAD. In this study, we examined the effects of moxifloxacin (MFLX), one of the fluoroquinolones, on the development of AAD in model mice.Methods and results: C57BL/6J mice (4-week-old) were fed a high-fat diet. At 8 weeks of age, the mice were started to infuse with saline or angiotensin Ⅱ (1000 ng min-1 day-1) via osmotic minipumps for 4 weeks and then these mice were orally administered water (vehicle) or MFLX (30 and 100 mg min-1 day-1) for last 3 weeks. AAD lesions were histologically analyzed. MFLX (30 and 100 mg min-1 day-1) induced AAD formation and elastin degradation in aortic tissues by H&E staining and EVG staining. Additionally, by western blot analyses, MFLX (100 mg min-1 day-1) decreased the protein expression of SM22a, one of the VSMC markers, in aortic tissues compared to vehicle and MFLX (30 mg min-1 day-1). Furthermore, MFLX (30 and 100 mg min-1 day-1) increased the protein expression of OPN, MMP-2, and -9 in aortic tissues.Conclusion: MFLX decreased the expression of SM22a and increased the expression of OPN and MMPs in aortic tissues from AAD model mice. Therefore, MFLX may induce the onset of AAD by weakening the aortic media.
- 1 January 2022
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 95, 2-141
Open AccessMoxifloxacin exacerbates aortic aneurysm and aortic dissection by weakening the aortic media
Backgrounds: Aortic aneurysm and dissection (AAD) are caused by weaking vessel wall and depletion of vascular smooth muscle cells (VSMC). Osteopontin (OPN) causes the onset and exacerbation of AAD by increasing expression of matrix metalloproteinases (MMPs). Fluoroquinolones are the most common used antibiotics. On the other hand, clinical studies have indicated that fluoroquinolones may be associated with an increased risk of AAD. In this study, we examined the effects of moxifloxacin (MFLX), one of the fluoroquinolones, on the development of AAD in model mice.Methods and results: C57BL/6J mice (4-week-old) were fed a high-fat diet. At 8 weeks of age, the mice were started to infuse with saline or angiotensin Ⅱ (1000 ng min-1 day-1) via osmotic minipumps for 4 weeks and then these mice were orally administered water (vehicle) or MFLX (30 and 100 mg min-1 day-1) for last 3 weeks. AAD lesions were histologically analyzed. MFLX (30 and 100 mg min-1 day-1) induced AAD formation and elastin degradation in aortic tissues by H&E staining and EVG staining. Additionally, by western blot analyses, MFLX (100 mg min-1 day-1) decreased the protein expression of SM22a, one of the VSMC markers, in aortic tissues compared to vehicle and MFLX (30 mg min-1 day-1). Furthermore, MFLX (30 and 100 mg min-1 day-1) increased the protein expression of OPN, MMP-2, and -9 in aortic tissues.Conclusion: MFLX decreased the expression of SM22a and increased the expression of OPN and MMPs in aortic tissues from AAD model mice. Therefore, MFLX may induce the onset of AAD by weakening the aortic media.
- 1 June 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 558, 94-101
Testosterone deficiency promotes the development of pulmonary emphysema in orchiectomized mice exposed to elastase
- 1 June 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 558, 94-101
Testosterone deficiency promotes the development of pulmonary emphysema in orchiectomized mice exposed to elastase
- Open Access
- 1 January 2021
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 94, 1-P2
Moxifloxacin exacerbate aortic aneurysm and aortic dissection by increasing osteopontin protein expressions
Backgrounds: Aortic aneurysm and dissection (AAD) are fatal diseases that are caused by the rapid destruction of the aortic wall. Osteopontin (OPN), an inflammatory extracellular matrix protein, is involved in the formation and development of AAD. Fluoroquinolones are among the most widely used antibiotics. On the other hands, recent clinical studies indicated an association between fluoroquinolone use and increased risk of AAD. However, this mechanism remains obscure. In this study, we examined the effects of moxifloxacin (MFLX), one of the fluoroquinolones, on the development of AAD in model mice and investigated OPN expressions in aortic tissues from AAD-model mice and in macrophages (RAW264.7 cell).Methods and results: C57BL/6J mice (4weeks of age) were fed a high-fat diet. Four weeks later (8weeks of age), the mice were infused with vehicle or angiotensin Ⅱ (1000 ng/min/day) via osmotic minipumps for 4 weeks. MFLX (30 and 100 mg/kg/day) or water (vehicle) was orally administered to these mice for last 3 weeks. MFLX (100mg/kg/day) caused to development of AAD in model mice. Additionally, OPN protein expressions were increased in aortic tissues from MFLX-treated mice compared with from vehicle-treated mice. Next, to examine the effects of MFLX on OPN expression in macrophages, RAW264.7 cells were treated with various concentration of MLFX for 24 h. MFLX dose-dependently increased OPN protein expressions in RAW264.7 cells; these increases reached at peak at 300 mM MFLX. In addition, OPN expressions in 300 mM MFLX-treated RAW264.7 cells were time-dependently increased and peaked at 24h.Conclusion: MFLX increased OPN protein expressions in aortic tissues from moderate-AAD model mice and in macrophages. Therefore, MFLX may induce the onset of AAD by increasing expression of OPN.
- 1 January 2021
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 94, 1-P2
Open AccessMoxifloxacin exacerbate aortic aneurysm and aortic dissection by increasing osteopontin protein expressions
Backgrounds: Aortic aneurysm and dissection (AAD) are fatal diseases that are caused by the rapid destruction of the aortic wall. Osteopontin (OPN), an inflammatory extracellular matrix protein, is involved in the formation and development of AAD. Fluoroquinolones are among the most widely used antibiotics. On the other hands, recent clinical studies indicated an association between fluoroquinolone use and increased risk of AAD. However, this mechanism remains obscure. In this study, we examined the effects of moxifloxacin (MFLX), one of the fluoroquinolones, on the development of AAD in model mice and investigated OPN expressions in aortic tissues from AAD-model mice and in macrophages (RAW264.7 cell).Methods and results: C57BL/6J mice (4weeks of age) were fed a high-fat diet. Four weeks later (8weeks of age), the mice were infused with vehicle or angiotensin Ⅱ (1000 ng/min/day) via osmotic minipumps for 4 weeks. MFLX (30 and 100 mg/kg/day) or water (vehicle) was orally administered to these mice for last 3 weeks. MFLX (100mg/kg/day) caused to development of AAD in model mice. Additionally, OPN protein expressions were increased in aortic tissues from MFLX-treated mice compared with from vehicle-treated mice. Next, to examine the effects of MFLX on OPN expression in macrophages, RAW264.7 cells were treated with various concentration of MLFX for 24 h. MFLX dose-dependently increased OPN protein expressions in RAW264.7 cells; these increases reached at peak at 300 mM MFLX. In addition, OPN expressions in 300 mM MFLX-treated RAW264.7 cells were time-dependently increased and peaked at 24h.Conclusion: MFLX increased OPN protein expressions in aortic tissues from moderate-AAD model mice and in macrophages. Therefore, MFLX may induce the onset of AAD by increasing expression of OPN.
- Open Access
- 1 June 2020
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 143 (2) , 106-111
Hesperidin blocks varenicline-aggravated atherosclerotic plaque formation in apolipoprotein E knockout mice by downregulating net uptake of oxidized low-density lipoprotein in macrophages
- 1 June 2020
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 143 (2) , 106-111
Open AccessHesperidin blocks varenicline-aggravated atherosclerotic plaque formation in apolipoprotein E knockout mice by downregulating net uptake of oxidized low-density lipoprotein in macrophages
- Open Access
- 1 January 2020
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 142 (1) , 9-15
Varenicline aggravates atherosclerotic plaque formation in nicotine-pretreated ApoE knockout mice due to enhanced oxLDL uptake by macrophages through downregulation of ABCA1 and ABCG1 expression
- 1 January 2020
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 142 (1) , 9-15
Open AccessVarenicline aggravates atherosclerotic plaque formation in nicotine-pretreated ApoE knockout mice due to enhanced oxLDL uptake by macrophages through downregulation of ABCA1 and ABCG1 expression